Our final conclusion is that TLR9 may be an effective therapeutic target in HDM-induced allergic asthma: treatment with anti-TLR9 inhibitory antibody abruptly increased IL-17A production by interfering with the TLR9–IL-2 axis. This evidence concerns the gene TLR9 and allergic asthma.